adenosine diphosphate has been researched along with olaparib in 5 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 5 (100.00) | 2.80 |
| Authors | Studies |
|---|---|
| Arenare, L; Baldassarre, G; Bartoletti, M; Califano, D; Capoluongo, E; Chiodini, P; Costi, MP; D'Incalci, M; Greggi, S; Marchini, S; Mezzanzanica, D; Musacchio, L; Normanno, N; Perrone, F; Pignata, S; Scala, S; Schettino, C | 1 |
| Alexandrov, LB; Altwerger, G; Andikyan, V; Azodi, M; Bellone, S; Choi, J; Clark, M; Harold, J; Hartwich, TMP; Huang, GS; Jeong, K; Manara, P; Manavella, DD; Menderes, G; Mutlu, L; Ratner, E; Santin, AD; Schwartz, PE; Tymon-Rosario, JR; Yang, K; Yang-Hartwich, Y; Zipponi, M | 1 |
| Aryal, N; Asher, R; Berton, D; Colombo, N; Freimund, AE; Frenel, JS; Huzarski, T; Kim, JW; Korach, J; Ledermann, JA; Lee, CK; Oza, AM; Park-Simon, TW; Pautier, P; Penson, RT; Pignata, S; Pujade-Lauraine, E; Sonke, GS; Tamura, K; Vidal, L | 1 |
| Chatterjee, S; Das, B; Dash, SR; Dhal, AK; Kundu, CN; Paul, S; Sinha, S | 1 |
| Lu, W; Shen, Y; Shen, Z; Tang, S; Wei, X; Xu, J | 1 |
1 trial(s) available for adenosine diphosphate and olaparib
| Article | Year |
|---|---|
Efficacy of subsequent chemotherapy for patients with BRCA1/2-mutated recurrent epithelial ovarian cancer progressing on olaparib versus placebo maintenance: post-hoc analyses of the SOLO2/ENGOT Ov-21 trial.
Topics: Adenosine Diphosphate; Antineoplastic Agents; BRCA1 Protein; BRCA2 Protein; Carcinoma, Ovarian Epithelial; Disease Progression; Female; Humans; Maintenance Chemotherapy; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
4 other study(ies) available for adenosine diphosphate and olaparib
| Article | Year |
|---|---|
Olaparib beyond progression compared with platinum chemotherapy after secondary cytoreductive surgery in patients with recurrent ovarian cancer: phase III randomized, open-label MITO 35b study, a project of the MITO-MANGO groups.
Topics: Adenosine Diphosphate; Antineoplastic Agents; Carcinoma, Ovarian Epithelial; Cytoreduction Surgical Procedures; Female; Humans; Mangifera; Neoplasm Recurrence, Local; Ovarian Neoplasms; Phthalazines; Piperazines; Platinum; Poly(ADP-ribose) Polymerase Inhibitors; Ribose | 2022 |
Homologous recombination deficiency (HRD) signature-3 in ovarian and uterine carcinosarcomas correlates with preclinical sensitivity to Olaparib, a poly (adenosine diphosphate [ADP]- ribose) polymerase (PARP) inhibitor.
Topics: Adenosine Diphosphate; Animals; Carcinosarcoma; Cell Line, Tumor; Female; Homologous Recombination; Humans; Ovarian Neoplasms; Ovary; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose | 2022 |
Combination of talazoparib and olaparib enhanced the curcumin-mediated apoptosis in oral cancer cells by PARP-1 trapping.
Topics: Adenosine Diphosphate; Amino Acids; Animals; Apoptosis; Cell Line, Tumor; Curcumin; DNA; Humans; Mice; Mouth Neoplasms; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Resveratrol; Ribose | 2022 |
Olaparib synergizes with arsenic trioxide by promoting apoptosis and ferroptosis in platinum-resistant ovarian cancer.
Topics: Adenosine Diphosphate; AMP-Activated Protein Kinases; Animals; Apoptosis; Arsenic Trioxide; Carcinoma, Ovarian Epithelial; Cell Line, Tumor; Female; Ferroptosis; Humans; Mice; Ovarian Neoplasms; Phthalazines; Piperazines; Poly(ADP-ribose) Polymerase Inhibitors; Poly(ADP-ribose) Polymerases; Ribose; Stearoyl-CoA Desaturase | 2022 |